Free Trial

Stifel Nicolaus Begins Coverage on Hinge Health (NYSE:HNGE)

Hinge Health logo with Services background

Equities researchers at Stifel Nicolaus started coverage on shares of Hinge Health (NYSE:HNGE - Get Free Report) in a report released on Monday,Briefing.com Automated Import reports. The firm set a "buy" rating and a $48.00 price target on the stock. Stifel Nicolaus' price target would suggest a potential upside of 38.09% from the company's current price.

Several other brokerages have also recently issued reports on HNGE. Canaccord Genuity Group started coverage on shares of Hinge Health in a report on Monday. They issued a "buy" rating and a $52.00 target price for the company. Bank of America assumed coverage on Hinge Health in a research note on Monday. They set a "buy" rating and a $42.00 price target for the company. Raymond James started coverage on Hinge Health in a report on Monday. They issued an "outperform" rating and a $45.00 price target for the company. KeyCorp began coverage on shares of Hinge Health in a report on Monday. They issued an "overweight" rating and a $45.00 price target for the company. Finally, Morgan Stanley assumed coverage on Hinge Health in a research report on Monday. They set an "overweight" rating and a $46.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $46.00.

Read Our Latest Report on HNGE

Hinge Health Stock Down 0.7%

HNGE stock opened at $34.76 on Monday. Hinge Health has a fifty-two week low of $33.42 and a fifty-two week high of $43.80.

About Hinge Health

(Get Free Report)

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Hinge Health Right Now?

Before you consider Hinge Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.

While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Oil Spikes Amid Rising Warfare: 3 Stocks to Watch Now
Palantir at All-Time Highs: Take Profits or Hold the Line?
3 Tech Stocks Insiders Are Buying: Speculative Plays for June

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines